Trial Selection: From Art To Science

By Yannis Jemiai, Chief Scientific Officer, Cytel

Recently, Cytel co-founder Professor Cyrus Mehta noted that, “Clinical trial design selection is too much like an art, and not enough like a science.” The ad hoc nature of some clinical trial selection processes, raise concerns about whether or not the optimal clinical trial has been chosen for a sponsor’s specific needs. Oftentimes, this means that sponsors cannot be confident in their designs, and sometimes leave millions of dollars on the table because more valuable design options were overlooked.

The new science of the re-imagined clinical trial makes trial selection more scientific by quantifying resource allocation and prioritization of commercial objectives, and then making data-driven clinical trial selection which provides a strong sense of opportunity costs. Continue reading below to learn about the science of clinical trial selection.